NASDAQ:CORT Corcept Therapeutics (CORT) Stock Forecast, Price & News $23.23 -0.03 (-0.13%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$22.84▼$23.3350-Day Range$21.63▼$25.1552-Week Range$17.86▼$30.14Volume470,938 shsAverage Volume770,565 shsMarket Capitalization$2.36 billionP/E Ratio28.33Dividend YieldN/APrice Target$26.71 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Corcept Therapeutics MarketRank™ ForecastAnalyst RatingHold2.43 Rating ScoreUpside/Downside15.0% Upside$26.71 Price TargetShort InterestBearish19.63% of Float Sold ShortDividend StrengthN/ASustainability-0.98Upright™ Environmental ScoreNews Sentiment0.24Based on 8 Articles This WeekInsider TradingSelling Shares$716,100 Sold Last QuarterProj. Earnings Growth-1.61%From $0.62 to $0.61 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsMedical Sector560th out of 985 stocksPharmaceutical Preparations Industry270th out of 486 stocks 2.2 Analyst's Opinion Consensus RatingCorcept Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.71, Corcept Therapeutics has a forecasted upside of 15.0% from its current price of $23.23.Amount of Analyst CoverageCorcept Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted19.63% of the float of Corcept Therapeutics has been sold short.Short Interest Ratio / Days to CoverCorcept Therapeutics has a short interest ratio ("days to cover") of 19.2, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldCorcept Therapeutics does not currently pay a dividend.Dividend GrowthCorcept Therapeutics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCorcept Therapeutics has received a 63.04% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sex hormones and modulators of the genital system (G03)", "Clinical research services for cancer", and "Clinical research services for metabolic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Corcept Therapeutics is -0.98. Previous Next 2.9 News and Social Media Coverage News SentimentCorcept Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Corcept Therapeutics this week, compared to 3 articles on an average week.Search Interest1 people have searched for CORT on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $716,100.00 in company stock.Percentage Held by Insiders18.60% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.08% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Corcept Therapeutics are expected to decrease by -1.61% in the coming year, from $0.62 to $0.61 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corcept Therapeutics is 28.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.17.Price to Earnings Ratio vs. SectorThe P/E ratio of Corcept Therapeutics is 28.33, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 102.89.Price to Book Value per Share RatioCorcept Therapeutics has a P/B Ratio of 4.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Corcept Therapeutics (NASDAQ:CORT) StockCorcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.Read More Receive CORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CORT Stock News HeadlinesJune 2, 2023 | msn.comCorcept (CORT) Down 4.3% Since Last Earnings Report: Can It Rebound?June 2, 2023 | americanbankingnews.comCorcept Therapeutics Incorporated Expected to Earn FY2023 Earnings of $0.59 Per Share (NASDAQ:CORT)June 5, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 26, 2023 | msn.comTruist Securities Maintains Corcept Therapeutics (CORT) Hold RecommendationMay 26, 2023 | americanbankingnews.comCorcept Therapeutics (NASDAQ:CORT) PT Lowered to $26.00 at Truist FinancialMay 25, 2023 | fool.comCorcept Therapeutics (NASDAQ: CORT)May 24, 2023 | benzinga.comCorcept Therapeutics Board Member Awarded $743K Worth of Stock OptionsMay 24, 2023 | americanbankingnews.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJune 5, 2023 | Legacy Research (Affiliate) (Ad)“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.May 17, 2023 | thestreet.comWhy Corcept Therapeutics (CORT) Is Plummeting TodayMay 10, 2023 | msn.comCorcept Therapeutics's Return On Capital Employed OverviewMay 10, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT) Lowered by HC WainwrightMay 7, 2023 | americanbankingnews.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Forecasted to Post Q3 2023 Earnings of $0.13 Per ShareMay 5, 2023 | markets.businessinsider.comSVB Securities Keeps Their Hold Rating on Corcept Therapeutics (CORT)May 5, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Corcept Therapeutics Incorporated Decreased by SVB Leerink (NASDAQ:CORT)May 4, 2023 | msn.comHC Wainwright & Co. Reiterates Corcept Therapeutics (CORT) Buy RecommendationMay 4, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Corcept Therapeutics (CORT)May 4, 2023 | americanbankingnews.comBrokerages Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Target Price at $26.83May 4, 2023 | americanbankingnews.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 3, 2023 | seekingalpha.comCorcept Therapeutics Incorporated (CORT) Q1 2023 Earnings Call TranscriptMay 3, 2023 | msn.comRecap: Corcept Therapeutics Q1 EarningsMay 3, 2023 | finance.yahoo.comCorcept Therapeutics (CORT) Lags Q1 Earnings EstimatesApril 27, 2023 | finance.yahoo.comStevanato Group (STVN) Earnings Expected to Grow: Should You Buy?April 13, 2023 | americanbankingnews.comCorcept Therapeutics (NASDAQ:CORT) Shares Down 2.7% April 12, 2023 | americanbankingnews.comCorcept Therapeutics Incorporated to Post FY2023 Earnings of $0.85 Per Share, SVB Leerink Forecasts (NASDAQ:CORT)April 11, 2023 | msn.comSVB Leerink Initiates Coverage of Corcept Therapeutics (CORT) with Market Perform RecommendationApril 11, 2023 | americanbankingnews.comCorcept Therapeutics (NASDAQ:CORT) Now Covered by SVB LeerinkSee More Headlines CORT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CORT Company Calendar Last Earnings5/03/2023Today6/05/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:CORT CUSIP21835210 CIK1088856 Webwww.corcept.com Phone(650) 327-3270Fax650-327-3218Employees238Year Founded1998Price Target and Rating Average Stock Price Forecast$26.71 High Stock Price Forecast$32.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+14.9%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$0.82 Trailing P/E Ratio28.34 Forward P/E Ratio37.48 P/E GrowthN/ANet Income$101.42 million Net Margins22.79% Pretax Margin26.04% Return on Equity19.37% Return on Assets16.91% Debt Debt-to-Equity RatioN/A Current Ratio6.77 Quick Ratio6.69 Sales & Book Value Annual Sales$401.86 million Price / Sales5.87 Cash Flow$0.97 per share Price / Cash Flow24.02 Book Value$4.66 per share Price / Book4.99Miscellaneous Outstanding Shares101,580,000Free Float82,686,000Market Cap$2.36 billion OptionableOptionable Beta0.50 Social Links Key ExecutivesJoseph K. BelanoffPresident, Chief Executive Officer & DirectorAtabak MokariChief Financial OfficerHazel HuntChief Scientific OfficerSean MaduckPresident-Corcept EndocrinologyWilliam GuyerChief Development OfficerKey CompetitorsSupernus PharmaceuticalsNASDAQ:SUPNPacira BioSciencesNASDAQ:PCRXPerrigoNYSE:PRGOJazz PharmaceuticalsNASDAQ:JAZZNuvalentNASDAQ:NUVLView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,126 shares on 5/26/2023Ownership: 0.013%Toroso Investments LLCSold 10,184 shares on 5/23/2023Ownership: 0.055%Ameriprise Financial Inc.Sold 10,910 shares on 5/22/2023Ownership: 0.357%Putnam Investments LLCSold 153,914 shares on 5/22/2023Ownership: 0.018%New York State Common Retirement FundBought 43,141 shares on 5/18/2023Ownership: 0.124%View All Insider TransactionsView All Institutional Transactions CORT Stock - Frequently Asked Questions Should I buy or sell Corcept Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CORT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CORT, but not buy additional shares or sell existing shares. View CORT analyst ratings or view top-rated stocks. What is Corcept Therapeutics' stock price forecast for 2023? 7 Wall Street research analysts have issued 1-year target prices for Corcept Therapeutics' stock. Their CORT share price forecasts range from $22.00 to $32.00. On average, they predict the company's share price to reach $26.71 in the next year. This suggests a possible upside of 14.9% from the stock's current price. View analysts price targets for CORT or view top-rated stocks among Wall Street analysts. How have CORT shares performed in 2023? Corcept Therapeutics' stock was trading at $20.31 on January 1st, 2023. Since then, CORT shares have increased by 14.4% and is now trading at $23.24. View the best growth stocks for 2023 here. When is Corcept Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our CORT earnings forecast. How were Corcept Therapeutics' earnings last quarter? Corcept Therapeutics Incorporated (NASDAQ:CORT) issued its quarterly earnings results on Wednesday, May, 3rd. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.20 by $0.06. The biotechnology company had revenue of $105.70 million for the quarter, compared to analysts' expectations of $104.91 million. Corcept Therapeutics had a trailing twelve-month return on equity of 19.37% and a net margin of 22.79%. The company's revenue was up 12.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.20 EPS. What ETFs hold Corcept Therapeutics' stock? ETFs with the largest weight of Corcept Therapeutics (NASDAQ:CORT) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), Acquirers Fund ETF (ZIG), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Quality ETF (XSHQ), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What guidance has Corcept Therapeutics issued on next quarter's earnings? Corcept Therapeutics updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $435.00 million-$455.00 million, compared to the consensus revenue estimate of $435.73 million. What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO? 6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Corcept Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI). What is Corcept Therapeutics' stock symbol? Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT." Who are Corcept Therapeutics' major shareholders? Corcept Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.88%), Ingalls & Snyder LLC (8.24%), Renaissance Technologies LLC (6.68%), State Street Corp (3.24%), Federated Hermes Inc. (2.72%) and Dimensional Fund Advisors LP (2.12%). Insiders that own company stock include Daniel N Swisher Jr, G Leonard Baker Jr, G Leonard Baker, Jr, Gary Charles Robb, Joseph Douglas Lyon, Joseph K Belanoff and Sean Maduck. View institutional ownership trends. How do I buy shares of Corcept Therapeutics? Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Corcept Therapeutics' stock price today? One share of CORT stock can currently be purchased for approximately $23.24. How much money does Corcept Therapeutics make? Corcept Therapeutics (NASDAQ:CORT) has a market capitalization of $2.36 billion and generates $401.86 million in revenue each year. The biotechnology company earns $101.42 million in net income (profit) each year or $0.82 on an earnings per share basis. How many employees does Corcept Therapeutics have? The company employs 238 workers across the globe. How can I contact Corcept Therapeutics? Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The official website for the company is www.corcept.com. The biotechnology company can be reached via phone at (650) 327-3270, via email at cjames@corcept.com, or via fax at 650-327-3218. This page (NASDAQ:CORT) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.